Phase 2 is mostly safety but efficacy data can be included. Usually secondary endpoints. There exist phase 2/3 trials. Anavex is running one utilizing adaptive clinical trial design. Groundbreaking stuff but it'll be interesting to see how the FDA proceeds.
Regarding CYDY, the country is desperate. Political expediency has allowed bad trials and meds to flourish. One can only hope a promising (and hopefully efficacious) drug has a fair shot even if coming from a small player. I could even envision "live trials" if the safety data is unassailable. We need something. The virus is winning.
News 
Market Data 
Discover 
